Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 21Breast Neoplasms 11Prostatic Neoplasms 10Fallopian Tube Neoplasms 8Neoplasms 7Neoplasm Metastasis 7Pancreatic Neoplasms 6Endometrial Neoplasms 5Triple Negative Breast Neoplasms 4Lung Neoplasms 3Head and Neck Neoplasms 3Glioblastoma 3Carcinoma, Ovarian Epithelial 3Small Cell Lung Carcinoma 2Prostatic Neoplasms, Castration-Resistant 2Glioma 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Biliary Tract Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Unilateral Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1SCLC,Extensive Stage 1Recurrence 1Rectal Neoplasms 1Prostate Adenocarcinoma 1

Interventions

Fulvestrant 5serabelisib 2sapanisertib 2ribociclib 2palbociclib 2Paclitaxel 2Letrozole 2Irinotecan 2Gemcitabine 2Carboplatin 2Alpelisib 2venetoclax 1tivozanib 1tipifarnib 1sotorasib 1pembrolizumab 1olaparib 1niraparib 1lorlatinib 1liposomal doxorubicin 1inavolisib 1exemestane 1encorafenib 1ceralasertib 1cemiplimab 1capivasertib 1binimetinib 1abemaciclib 1Taxes 1Tamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × niraparib × 1 year × Clear all
NCT06433219 2026-06-03

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

EMD Serono

Phase 2 Active not recruiting
63 enrolled
Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡